OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Trading Down 13.2 %

Shares of NASDAQ OPGN opened at $1.65 on Thursday. The stock has a fifty day moving average of $1.92 and a 200-day moving average of $2.99. OpGen has a fifty-two week low of $1.61 and a fifty-two week high of $9.90.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.

Institutional Investors Weigh In On OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp purchased a new stake in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors own 2.68% of the company’s stock.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.